Bone Marrow Transplant as Definitive Therapy for β-Thalassemia Major Patients: A literature review

Thalassemia is a group of hereditary hemoglobin disorders characterized by insufficient production at least one globin chain, resulting in unbalanced chains. Homozygous mutations the β-globin gene, absence β-chain, are main cause β-thalassemia major. Because β-chain major not formed, there an accumulation free α-chains red blood cells, which can trigger apoptosis and hemolysis ineffective erythropoiesis. Management for patients requires lifelong therapy with transfusions medication. However, routine administration iron chelation drugs cannot cure be cured through definitive therapies including bone marrow or stem cell transplantation genetic therapy. Bone treatment option children adolescents suffering from certain types cancer other such as thalassemia.